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Design: Retrospective study.
Setting: Genetics laboratories.
Patient(s): PGS cycles during which either mosaic or euploid embryos were replaced.
Intervention(s): Blastocysts were biopsied and processed with the use of NGS, followed by frozen embryo transfer. Trophectoderm (TE)
biopsies were classiﬁed as mosaic if they had 20%–80% abnormal cells.
Main Outcome Measure(s): Implantation, miscarriage rates, and ongoing implantation rates (OIRs) were compared between euploid
and types of mosaic blastocysts.
Result(s): Complex mosaic embryos had a signiﬁcantly lower OIR (10%) than aneuploidy mosaic (50%), double aneuploidy mosaic
(45%), and segmental mosaic (41%). There was a tendency for mosaics with 40%–80% abnormal cells to have a lower OIR than those
with<40% (22% vs. 56%). However, few embryos (n¼ 34) with a mosaic error in 40%–80% of the TE sample were replaced. There was
no difference between monosomic and trisomic mosaics or between entire chromosome mosaicism or segmental mosaicism. Implan-
tation rates were signiﬁcantly higher (70% vs. 53%), miscarriage rates lower (10% vs. 25%), and OIRs higher (63% vs. 40%) after euploid
embryo transfer than after mosaic embryo transfer.
Conclusion(s): Forty-one percent of mosaic embryos produced an ongoing implantation. Complex mosaic blastocysts had a lower OIR
than other mosaics. Mosaic monosomies performed as well as mosaic trisomies and mosaic segmental aneuploidies. The results suggest
that embryos with >40% abnormal cells and those with multiple mosaic abnormalities (chaotic mosaics) are likely to have lower OIRs
and should be given low transfer priority. (Fertil Steril 2017;108:62–71.2017 The Authors. Published by Elsevier Inc. on behalf of the
American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).)
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Fertility and Sterility®M osaicism has been described in human embryossince the beginning of preimplantation geneticscreening (PGS) for aneuploidy (1–4). Although
meiotically derived aneuploidy was found to increase with
advancing maternal age, there was no clear relationship
with other embryologic factors, such as dysmorphism
(deﬁned as presence of multinucleation, fragmentation, and
unevenness) (5, 6). Conversely, other types of chromosome
abnormalities, such as mosaicism occurring due to post-
zygotic malsegregation, polyploidy, and haploidy, were
found to increase with dysmorphism, but not with maternal
age, with the exception of aneuploid embryos carrying a com-
bination of meiotic and mitotic (mosaic) errors (5,7–12).
Whole cleavage-stage embryo analysis, with strict criteria
to classify an embryo as mosaic if at least two of its cells
are abnormal, showed that 30% of them were mosaic (12).
On the other hand, lower rates of mosaicism have been
detected in blastocysts (13–17).
With the advent of molecular techniques (array compara-
tive genome hybridization [aCGH], single-nucleotide polymor-
phism array, quantitative polymerase chain reaction [qPCR],
next-generation sequencing [NGS]), the DNA of all of the cells
in the biopsy is analyzed as a single entity and compared to a
control DNA sample. This has therefore precluded the analysis
of mosaicism. In addition, some of these techniques do not
have enough sensitivity to detect the presence of mosaicism
in a biopsied embryo sample. Array CGH, the most widely
used of these methods, can not detect mosaicism with a great
degree of accuracy. The software used for aCGH analysis
(Bluefuse; Illumina) has not been validated for mosaicism
detection, and a noisy proﬁle or a mosaic proﬁle could look
alike. With perfect proﬁles, we would be comfortable detecting
40%–60% mosaicism. Below 40% we would classify it as
normal and above 60% as abnormal. Recently Greco et al.
(18) reported a 4.8% rate of mosaicism (mosaicism range
35%–50%), compared with 15%–37% with the use of ﬂuores-
cence in situ hybridization (FISH) (15–17,19).
In the past few years another technique, NGS, was vali-
dated and then implemented for PGS (20–23). NGS has a
higher dynamic range compared with aCGH, and it can
detect the presence of 20%–80% abnormal cells in a
blastocyst biopsy (21, 24, 25). There are several different
NGS platforms, and not all of them can detect mosaicism to
the same extent, because they have different resolutions.
The platform we use is based on Illumina's Veriseq NGS
strategy (high-resolution NGS [hr-NGS]) can detect mosai-
cism when aneuploidy is present in 20%–80% of TE cells bio-
psied from a blastocyst. Considering that a blastocyst biopsy
has on average 5–10 cells, we are able to detect mosaicism be-
ing present in 1/5 (20%) to 4/5 (80%) of the TE cells. With the
use of hr-NGS, we reported 21% of embryos to contain
euploid/aneuploid cell lines and 10% aneuploid/aneuploid
(but with different aneuploid cell lines) (26). These ﬁndings
are similar to the historical data obtained with the use of
FISH when analyzing all cells individually. In addition, and
similarly to the FISH data, we did not observe an increase
of mosaicism rates with advancing maternal age (26). This
preliminary work demonstrated that hr-NGS is a much
more sensitive method, compared with aCGH and canVOL. 108 NO. 1 / JULY 2017accurately identify the presence of mosaicism (24, 27).
Another NGS platform, CNV-Seq (23), can also detect
20%–80% mosaicism, but in that study only 13% of embryos
were classiﬁed as mosaic. Lower-resolution NGS, such as
Embryvu, has not reported the detection of mosaicism.
The ability of hr-NGS to accurately identify mosaicism in
TE samples has led to signiﬁcant disagreement and confusion
regarding the biologic meaning of these ﬁndings. A recent
investigation has even suggested that low-level mosaicism
is indistinguishable from technical background noise (28).
Another opinion paper (29) suggested that mosaicism detec-
tion is ﬂawed, because if the same amount of trisomic and
monosomic cells are present in a TE biopsy, then the average
result will be of euploidy. However, a preliminary study (30) in
which several biopsies from the same embryo were analyzed
with the use of hr-NGS found that only two out of 28 embryos
had monosomic and trisomic cell lines for the same chromo-
some abnormality, suggesting that this event is rare, because
by the time the embryo reaches the blastocyst stage one of the
abnormal cell lines has taken over, or compartmentalization
is unlikely to produce that result.
There is also scant information on the clinical implica-
tions of replacing embryos classiﬁed as mosaic by means of
hr-NGS. After replacing 44 mosaic blastocysts classiﬁed as
such by means of hr-NGS but euploid by means of aCGH,
38% (17/44) implanted but 29% (5/17) of those miscarried,
compared with 57% (29/51) implanting and 24% (5/29) mis-
carrying for a well matched control euploid embryo group
(27). This is similar to 38% implantation rate after replacing
mosaic embryos identiﬁed by means of aCGH (18). The differ-
ence between these two studies is that hr-NGS detects many
more mosaic blastocysts than aCGH (29% vs. 5%).
In another study, reanalysis bymeans of hr-NGS of surplus
DNA from embryos classiﬁed as euploid by means of aCGH
that ended up in miscarriage showed that 46% were euploid
and the rest mosaic or polyploid (31). Using the same approach,
we also found signiﬁcantly more mosaic embryos in lost preg-
nancies than in ongoing pregnancies (P¼ .0062) (24). The
miscarriage rate after replacing embryos classiﬁed as euploid
by means of NGS has been determined to be 6%, compared
with 13% for aCGH (32) and 20% for qPCR (33).
Thus the evidence suggests that embryos classiﬁed as being
mosaic by means of NGS miscarry more and implant less, but
40% of them can still result in a viable pregnancy. To date
there is little information about which of these NGS mosaics
have the highest chance to make a viable pregnancy. Therefore
the purpose of the present study was to retrospectively analyze
the pregnancy outcomes of replaced mosaic embryos and
compare them to the type of mosaicism seen according to
several different criteria, such as percentage of abnormal cells,
chromosome abnormality type (segmental, trisomy, mono-
somy, complex abnormal), and chromosomes involved.METHODS
Patients and Embryos
This study included patients that received transfer of mosaic
embryos only and for which the clinical outcome was known.
Forty-four of these embryos (series 1) were included in a63
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embryo transfers (DETs) and 34 single-embryo transfers
(SETs). Of the DETs, one transfer resulted in both mosaic
embryos producing ongoing pregnancies, and the other four
transfers did not lead to a pregnancy. The other 99 embryos
(series 2), were generated in three different centers; these
embryos were all replaced in SETs.
Comparison Group
The four centers participating in the study were asked to pro-
vide control groups of transferred euploid embryos, which
were previously analyzed by means of PGS with the use of
hr-NGS. The patients generating the control-group embryos
were well matched for female age to the patients generating
the mosaic embryos. Patients in test and control groups
were undergoing IVF treatment in combination with PGS
during the same period of time with the test group patients.Determination of Mosaicism Detection and Types
of Mosaic Blastocysts
The platform that we used during this study, which we are
characterizing as hr-NGS, was the Veriseq NGS (Illumina).
The Veriseq NGS strategy interrogates 24 million sequence
reads, so with a loss of 30%–40% reads per run, and analyzing
24 samples per experiment, it provides 600,000–900,000
reads per sample and can detect the presence of mosaicism
with a resolution of 20%–80% in a biopsied sample. The
cytogenetic analysis of biopsied samples was performed
with the Bluefuse Multi v3 software for NGS, which provided
copy number counts for each chromosome pair. Although it is
true that the software will automatically highlight abnormal
chromosomes when such errors are present in >50% of the
TE sample, internal validation demonstrates a technical accu-
racy down to 10% resolution. Therefore, diagnostic decisions
were made based on speciﬁc copy number variations. A chro-
mosome with two copies received a value equal to 2 (euploid),
a chromosome with one copy (monosomy) received a value of
1, and a chromosome with three copies (trisomic) received a
value of 3. Values between these numbers were considered
to represent mosaic abnormalities, with samples with values
between 1 and 2 being considered mosaic monosomies, and
those between 2 and 3 mosaic trisomies. An embryo biopsy
with a segmental (or partial) aneuploidy had either a piece
of a chromosome having a value of 1 (partial monosomy) or
of 3 (partial trisomy). The Veriseq NGS technique can detect
extra or missing chromosome segments as small as 1.5 Mb
in size. Values for segmental abnormalities between 1 and 2
were classiﬁed as mosaic partial monosomies and those
between 2 and 3 as mosaic partial trisomies (combined we
call them mosaic segmental). TE samples that had two mosaic
abnormal chromosomes were classiﬁed as double mosaic
(regardless of whether these errors were a combination of
two whole-chromosome events, two segmental events, or
one segmental and one whole-chromosome event), and those
with three or more mosaic chromosomes were characterized
as complex mosaic.
Using the numeric values given by the software, which
have been validated ﬁrst through mixing experiments64(see below), we were able to determine the percentage of
abnormal cells in the TE biopsies analyzed.
The Reprogenetics position is that mosaicism <20% or
>80% can not be differentiated from technical noise, there-
fore, <20% mosaics should be classiﬁed as euploid and
>80% as aneuploid. For this study we grouped embryos in
20%–40% and >40%–80% groups to determine if low and
high rates of abnormal cells have an impact on ongoing
implantation rates (OIRs).
We used our electronic medical records database (eIVF;
Practicehwy.com), which provided us with some of the follow-
up information obtained for the study, and the rest was provided
by direct feedback from the centers not using eIVF.
Samples for centers 1 and 2 were processed by Reproge-
netics (US Labs), samples for center 3 by Genesis Genetics,
and samples for center 4 (series 1) by Reprogenetics UK. All
three companies are subsidiaries of Cooper Genomics.Mixing Experiments for Validation of Mosaicism
We recently published a series of dilution experiments
involving the mixture of euploid and aneuploid cell lines (24,
27). The aneuploid cells were isolated from ﬁbroblast cell
lines obtained from the National Institute of General Medical
Sciences Human Genetic Cell Repository at the Coriell
Institute for Medical Research (USA). These were combined
with euploid male (46,XY) lymphocytes in different ratios,
i.e., 0 aneuploid cells and 5 euploid cells, 1 aneuploid cell
and 4 euploid cells (20% abnormal), 2 aneuploid cells and 3
euploid cells (40% abnormal), 3 aneuploid cells and 2 euploid
cells (60% abnormal), 4 aneuploid cells and 1 euploid cell
(80% abnormal), and 5 aneuploid cells (100% abnormal).
Gains affecting entire chromosomes were examined with the
use of two male cell lines with trisomy 13 (47,XY,þ13:
GM00526) and trisomy 18 (47,XY,þ18: GM01359) and an
XXY trisomy 21 cell line (48,XXY,þ21: GM04965). Losses
affecting entire chromosomes were examined with the use of
a 45,X0 cell line (45,X0: GM00857). Partial chromosome
losses and gains were examined with the use of two
male and one female cell lines carrying a partial loss of
10p [46,XY,del(10)(p14p12): GM03047], a partial loss of
13q [46,XX,del13(pter>q14): GM00509], and an unbalanced
translocation between chromosomes 21 and X
[46,XX,der(21)(21qter>21p11::Xqter): GM01730]. The
mixing experiments were repeated three times, and each time
a different ampliﬁed DNA product resulting from mixing
normal and aneuploid cells was investigated. The aneuploid
cell lines carrying the segmental errors affecting
chromosome 13 (GM00509) and chromosome X (GM01730)
did not grow very well in culture. We were therefore able to
analyze samples isolated from these two cell lines only once.
In addition, DNA ampliﬁed from embryos with four
different structural abnormalities, 46,XX; del(6)(q25.3-qter),
dup(21)(q21.2-qter), 46,XX; dup(14)(q31.3-qter), del(18)(q22.1-
qter), 46,XY; del(14)(q31.3-qter), dup(18)(q22.1-qter), and
46,XY; dup(13)(pter-q22.3), del(18)(pter-q12.2), were mixed in
the same above ratios with euploid DNA in quantities equivalent
to 5 cells. Figure 1 shows different ratios of 46,XY to 46,XX;
del(6)(q25.3-qter), dup(21)(q21.2-qter) cells.VOL. 108 NO. 1 / JULY 2017
FIGURE 1
Ratio of 46,XY to 46,XX; del(6)(q25.3-qter), dup(21)(q21.2-qter) cells: (A) 5:0 (100%:0%), (B) 4:1 (80%:20%), (C) 3:2 (60%:40%), (D) 2:3
(40%:60%), (E) 1:4 (20%:80%), (F) 0:5 (0%:100%).
Munne. Pregnancy outcome of mosaic blastocysts. Fertil Steril 2017.
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TABLE 1
Center comparison of mosaic and control embryos.
Parameter
Center 1 Center 2 Center 3 Center 4 (series 1) Total
Difference
among centersMosaic Euploid Mosaic Euploid Mosaic Euploid Mosaic Euploid Mosaic Euploid
Age (y) 37.7 35.8 39.0 39.2 34.1 35.2 37.3 37.9 35.8 37.3
Embryos replaced, n 13 201 11 478 75 315 44 51 143 1,045
Implanted, n 5 142 9 355 47 210 15 29 76 736
Implantation rate, % 38 71 82 74 63 67 34 57 53 70
P value NS NS NS NS NS NS
Embryos lost, n 4 11 2 28 10 31 3 5 19 75
Fetal loss rate, % 80 8% 22 8 21 15 20 17 25 10
P value .004 NS NS NS .002 NS
Ongoing implantations, n 1 131 7 327 37 179 12 24 57 661
Ongoing implantation rate, % 8 65 64 68 49 57 27 47 40 63
P value .02 NS NS NS .006 NS
Note: NS ¼ not signiﬁcant.
Munne. Pregnancy outcome of mosaic blastocysts. Fertil Steril 2017.
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The variables of interest were the implantation rate (IR; em-
bryos implanting/embryos replaced), with implantation
deﬁned as the presence of a fetal sac (detected during the
6–10-week ultrasound), fetal loss rate (FLR; embryos lost/em-
bryos implanting), and OIR (IR  FLR).
Two types of statistical analyses were performed. A global
one was used to determinewhich variables were globally signif-
icant to explain IR (with value of 1 if embryo resulted in a preg-
nancy, 0 if not), FLR (with value of 1 if embryo resulted in a fetal
hart, 0 if not), and OIR (with value of 1 if embryo resulted in anTABLE 2
Pregnancy outcome of mosaic embryos according to mosaicism type, per
Mosaic type % Abnormal No. of cycles
Impl
n
Complex 20–40 17 2
>40–80 4 0
Double 20–40 22 11
>40–80 7 5
Monosomic 20–40 28 20
>40–80 6 2
Trisomic 20–40 17 11
>40–80 3 1
Segmental 20–40 25 17
>40–80 14 7
20–40, all 109 61
>40–80, all 34 15
Single aneuploid 20–40 45 31
>40–80 9 3
Complex, all 21 2
Double, all 29 16
Aneuploid, all 54 34
Segmental, all 39 24
No. of chromosomes involved
1 93 58
2 29 16
R3 21 2
Total 143 76
Note: NS ¼ not signiﬁcant.
Munne. Pregnancy outcome of mosaic blastocysts. Fertil Steril 2017.
66ongoing pregnancy, 0 if not). Each one of these variables was
ﬁtted to a general linear mixed model (GLMM) with a logit
link function to study the effect of the center random factor
and all the ﬁxed effects considered in the study, such as
maternal age (x1), highest mosaic percentage (x2), mosaic group
(x3), and percentage of abnormal cells (x4). After checking that
the effect of this random variable was not signiﬁcant, there was
no need of creating a GLMM model, so we proceeded to adjust
the data with the use of a simpler logistic model. This model
included only the aforementioned ﬁxed effects. The analytic
expression of the model for OIR variable was:centage abnormal cells, and chromosomes involved.
anted Lost Ongoing
P value
% n % n %
12 0 0 2 12 NS
0 0 0 0 0
50 2 18 9 41 NS
71 1 20 4 57
71 6 30 14 50 NS
33 0 0 2 33
65 0 0 11 65 NS
33 1 100 0 0
68 7 41 10 40 NS
50 1 14 6 43
56 15 25 46 42 NS
44 3 20 12 35
69 6 19 25 56 .059
33 1 33 2 22
10 0 0 2 10 < .005
55 3 19 13 45
63 7 21 27 50
62 8 33 16 41
62 15 26 43 46 < .005
55 3 19 13 45
10 0 0 2 10
53 18 24 58 41
VOL. 108 NO. 1 / JULY 2017
TABLE 3
Chromosome abnormalities detected by means of next-generation
sequencing by Reprogenetics (US Labs).
Abnormality n (%)
Euploid 12,516 (42.87)
Aneuploid 5,751 (19.70)
Complex abnormal 3,477 (11.91)
Triploid 246 (0.84)
Full segmental 837 (2.87)
Mosaic aneuploid 2,789 (9.55)
Mosaic segmental 2,143 (7.34)
Complex mosaic 1,436 (4.92)
Total embryos 29,195
Munne. Pregnancy outcome of mosaic blastocysts. Fertil Steril 2017.
Fertility and Sterility®logitðPðOIR ¼ 1ÞÞ ¼ log

PðOIR ¼ 1Þ
PðOIR ¼ 0Þ

¼ aþ
X4
i¼1
bi,xi
Where a is the interception and bi the coefﬁcient for each
ﬁxed variable xi.
Analogous models were estimated for the other two
dependent variables, IR and FLR.
A second statistical analysis consisted of a single-
variable analysis to study differences at different scales.
This single-variable study was performed with the use of
chi-square and analysis of variance (ANOVA) when it was
needed.Institutional Review Board and Consenting of
Patients
Patients undergoing PGS in the United States signed informed
consents stating the risks of replacing embryos with mosai-
cism. For purposes of PGS analysis of collected and deidenti-
ﬁed data, we used the Aspire IRB HIPAA waiver of
authorization protocol PGSP 2015. Patients undergoing
PGS at Reprogenetics UK were consented as described in
Fragouli et al. (27).
Patients included in this study had consented to PGS with
the use of aCGH or NGS. We considered the study to be
exempt from Institutional Review Board approval. According
to the common rule 45 CFR 46.101(b) (4), exemptions include
‘‘research involving the collection or study of existing data,
documents, records, pathologic specimens if these sources
are publicly available or if the information is recorded by
the investigator in such a manner that subjects can not be
identiﬁed, directly or through identiﬁers linked to subjects.’’
A retrospective chart review was performed with the use
of a secure electronic medical record (eIVF) of patients with
embryos that underwent PGS.RESULTS
Mixing Experiments
Supplemental Table 1 presents the results of mixing
aneuploid and euploid cells in groups of 5:0 cells (100%
abnormal), 4:1 cells (80%), 3:2 cells (60%), 2:3 cells (40%),
and 1:4 cells (20%) to mimic diploid-aneuploid mosaicism.VOL. 108 NO. 1 / JULY 2017(Supplemental Tables 1–5 are available online at
www.fertstert.org.) The results obtained matched the
expected ratios and provided an SD. These experiments
were further complemented with DNA equivalent of 5 cells
mixed in the same ratios of euploid and a structural
abnormality, as presented in Supplemental Table 2. Again,
the experiments detected ratios similar to what would be
expected from these ratios.Clinical Outcomes
A total of 143 mosaic embryos from six centers. The partici-
pating patients had an average maternal age of 35.8 years.
The outcome of each embryo, cytogenetic results, and other
pertinent information is provided in the Supplemental
Table 3. Overall, they resulted in a 53% (76/143) IR, 24%
(18/76) FLR, and 41% (58/143) OIR.
These results are compared in Table 1 with a set of
matched controls. Overall, the IR seemed to be lower for
mosaic compared with euploid embryos (53% vs. 71%) but
this difference was not signiﬁcant (P>.05). However, the
FLR was signiﬁcantly higher (24% vs. 10%; P¼ .002) and
OIR lower (41% vs. 63%; P< .006) after the transfer of mosaic
embryos.
The pregnancy outcome results of replaced mosaic
embryos were further stratiﬁed according to type of mosaic
abnormality scored, number of chromosomes involved, per-
centage of abnormal cells, and chromosome types involved.
Table 2 summarizes those results. In summary, only complex
abnormal mosaics, those with three or more chromosomes
involved, had a signiﬁcantly (P< .001) reduced OIR (10%),
compared with mosaic single aneuploid (mosaic trisomic þ
mosaic monosomic: 50%), double mosaic (45%), and mosaic
segmental (41%).
As a reference, there were 4.92% complex abnormal
embryos in the Reprogenetics (US Labs) database of NGS-
analyzed embryos (Table 3).
Within each of the mosaic type categories, there was no
signiﬁcant difference between embryos with 20%–40%
abnormal cells and embryos with>40% abnormal cells. Over-
all, embryos with 20%–40% abnormal cells had an OIR of
42% and those with >40% abnormal cells had an OIR of
35%, but owing to the small sample size these differences
were not signiﬁcant (P¼ .1). Similarly, there was no difference
between mosaic monosomy or mosaic trisomy regarding OIR.
However, complex mosaics had a signiﬁcantly lower OIR
(10%) than the other mosaic embryos (P< .005). We did not
see signiﬁcant differences between single-chromosome
mosaic embryos (46% OIR) and double-chromosome mosaic
embryos (45% OIR).
Because there was no difference between embryos with a
single mosaic monosomy or a single mosaic trisomy, we
analyzed the subgroup of aneuploid mosaic embryos as a
whole, subdividing it into those with 20%–40% abnormal cells,
which had an OIR of 56%, and those with >40% abnormal
cells, which had an OIR of 22%, a nonsigniﬁcant difference
(P¼ .142) owing to the small size of the >40% group.
Regarding the chromosome number involved
(Supplemental Table 4), we grouped chromosomes 1–12 in67
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The OIR was similar, 45% and 43%, respectively. The only
difference was that chromosomes 1–12 involved more
segmental mosaic events (56%) than the smaller chromo-
somes (21%; P< .0001).
Of the chromosome abnormalities that could reach
term as full aneuploidies (chromosomes 13, 18, 21, X/Y) or
be involved in uniparental disomy (UPD; chromosomes 7,
14, 15), few trisomies or monosomy X were replaced
(Supplemental Table 4): Three monosomy X mosaics were re-
placed, resulting in one ongoing and twomiscarried pregnan-
cies; three monosomy 21 mosaics and one trisomy 21 mosaic
were replaced, resulting in two lost pregnancies; two mono-
somy 13 mosaics resulted in one ongoing and one miscarried
pregnancy, four monosomy 18 mosaics resulted in two
ongoing pregnancies; one monosomy 7 mosaic resulted in
an ongoing pregnancy; two monosomy 15 mosaics resulted
in one ongoing pregnancy, two monosomy 14 mosaics re-
sulted in one ongoing pregnancy; and one trisomy 14 mosaic
resulted in an ongoing pregnancy (Supplemental Table 3).
Unfortunately we were unable to collect karyotyping
information on the miscarriages, ongoing pregnancies, or
live-born babies.
We also analyzed differences among the four centers.
Table 1 shows that there were no signiﬁcant differences
seen between these four centers regarding IR, FLR, and OIR.
This is in agreement with the results of the GLMM model
including the variable center as a random factor which turned
out to be nonsigniﬁcant (P¼ .877).
Maternal age was not related to the percentage of
abnormal cells, with embryos with 20%–40% abnormal cells
having an average maternal age of 36.6 years and embryos
with >40% abnormal cells having an average age of
35.7 years. Embryos with one chromosome abnormality had
an average age of 35.4 years, those with two 36.1 years,
and those with three 36.8 years, but these differences were
not statistically signiﬁcant (P¼ .915; ANOVA).
Themultivariable analysis led to the conclusion that only the
mosaic type variable is signiﬁcant for explaining IR (P¼ .013).
However, none of the ﬁxed effects that were considered turned
out to be signiﬁcant for explaining the dependent variable OIR,
except a new dichotomic variable x5 that simply speciﬁes if a
mosaic is complex (x5 ¼ 1) or not (x5 ¼ 0). This added variable
turns out to be the only signiﬁcant variable in the logistic model
for OIR (P¼ .009). It would be interesting to perform this analysis
againwhenwehavemore data, because, although themosaicism
type is not signiﬁcant as far as explaining OIR is concerned, it
currently shows a slight tendency (P¼ .068) that led us to postu-
late about a possible effect of the mosaicism type. However, as
already mentioned, the data are insufﬁcient at this stage to
draw more deﬁnite conclusions. As far as the FLR is concerned,
no logistic model was obtained owing to the small number of
samples with FLR ¼ 1. Supplemental Table 5 presents the esti-
mated coefﬁcients for each level of the signiﬁcant independent
variables in the logistic model. As we can see in that table, the
odds of OIR for a sample classiﬁed as noncomplex is 7.3 times
larger than for another sample classiﬁed as complex. As far as
the IR is concerned, we can conclude from Supplemental
Table 5 that implantation is 17.4 times more probable for an68embryo with a mosaic monosomy than for a complex one. Like-
wise, embryoswith twoormore errors, aswell as partialmosaics,
are, respectively, 11.7, 14.3 and 9.0 times more likely to implant
than a complex ones.DISCUSSION
There is limited evidence about the developmental fate and
implantation ability of mosaic embryos. Recent studies using
comprehensive chromosome screening methodology indicate
that they miscarry more (24, 27, 31) and implant less (27), but
40% of them can still result in a viable pregnancy (18, 27).
Our investigation of a much larger data set supports earlier
observations that 41% of mosaic embryos can result in
ongoing pregnancy if they are transferred. Additionally,
we demonstrate for the ﬁrst time that the implantation
potential differs markedly among the various types of
mosaic blastocysts. Speciﬁcally, our results indicate that
embryos that have multiple mosaic errors (complex mosaic)
implant signiﬁcantly less than embryos with one or two
chromosomes in mosaic form.
The observation that complex mosaic embryos result in
very few ongoing pregnancies coincides with preliminary
data from another study in which mosaic blastocysts were
dissected into inner cell mass (ICM) and several different TE
parts (30). The results showed that complex mosaic embryos
had very few euploid ICM cells, whereas the rest of the em-
bryos had 40% normal ICMs. In contrast, fully abnormal
nonmosaic embryos had no normal ICMs (30). Of all the
embryos in the Reprogenetics (US Labs) database, 4.5%
were characterized as complex mosaic. Such embryos are
likely to have a very low chance of reaching term.
Another important observation of this study is that
mosaic monosomies and mosaic trisomies have similar
OIRs. This particular ﬁnding suggests that the recently
published Preimplantation Genetic Diagnosis International
Society (PGDIS) guidelines recommending that ‘‘embryos
showing mosaic euploid/monosomic embryos are preferable
to euploid/trisomic ones, given that monosomic embryos
(except 45, X) are not viable’’ (34) should be changed.
Although anaphase lag could be a mechanism of mitotic
mosaicism, early FISH mechanistic studies on mosaic em-
bryos showed that only 5% (28/556) of aneuploid mosaics
were caused by anaphase lag; the rest were due to nondisjunc-
tion (8). This means that most aneuploid mosaic embryos start
with normal, monosomic, and trisomic cell lines, and either
one of them is sampled more often or one of the cell lines
proliferates more than the others. According to the dissection
experiments from Garrisi et al. (30), the later mechanism is
probably more common, because only one of the embryos
dissected contained two complementing mosaic lines
(a monosomic and a trisomic one) whereas the others had
only one line per mosaic chromosome.
Experiments performed on mice demonstrated that some
cell lines grow faster and displace the slower ones (35). In that
mosaic model, highly abnormal cells (i.e., equivalent to com-
plex mosaic embryos) were combined in 1:1 and 1:3 ratios. In
those with a 1:1 ratio, the abnormal cells developed slower,
and the normal cells eventually took over and producedVOL. 108 NO. 1 / JULY 2017
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cells produced fewer pups (35). These experiments suggest
that abnormal cells are not capable of self-correcting but
have a tendency to divide more slowly than normal cells,
and the normal cells, if the proportion is large enough, take
over. in addition, these experiments showed that the distribu-
tion of abnormal cells was not clonal, but that they distributed
evenly and allocated to both TE and ICM (35). One would
expect similar results in the human and a correlation between
abnormal cell load in mosaic embryos and OIRs. However,
owing to our small sample size, we were unable to see a cor-
relation between percentage of abnormal cells and OIR
(P¼ .14). A large number of abnormal cells present in the
entire embryo is likely to be indicative of a lower chance of
ongoing implantation. It is unknown, however, if a large
number of abnormal cells in a single 5–10-cell TE biopsy
can accurately represent the chromosome constitution of
the remaining of the embryo. This could explain why some
embryos with >40% mosaic errors in the TE biopsies are
capable of implanting.
Our study also clariﬁed that there is no correlation be-
tween the type of chromosome affected by mosaicism and
OIRs. Almost all chromosome types in mosaic form were
compatible with ongoing pregnancy (except chromosome
17), and large chromosomes had an OIR identical to small
chromosomes. It should be noted that large chromosomes
had signiﬁcantly more segmental mosaic abnormalities
(P< .0001) than smaller ones. This was expected, because
chromosome size could play a role in the mechanisms leading
to breakage and segmental anomalies (36).
Of the chromosome abnormalities that could reach term
as full aneuploidies (chromosomes 13, 18, 21, X/Y) or be
involved in UPD (chromosomes 7, 14, 15), few trisomies
were replaced, probably because of the associated risk. Specif-
ically, embryos carrying 19 monosomies and four trisomies
for those chromosomes were replaced resulting in nine
ongoing pregnancies and three miscarriages. Follow-up for
these pregnancies is continuing.
The multivariate analysis conﬁrmed that female age had
no inﬂuence on OIR. This is consistent with observations from
the replacement of chromosomally normal embryos in which
IR and FLR were not affected by advancing maternal age (37).
On the other hand, mosaicism rates could be fertility cen-
ter related. We previously reported that mosaicism can be
caused by different culture conditions (38). More recently it
has been postulated that changes in culture media can lead
to different rates of mosaicism (39). Indeed, mosaicism rates
in egg donors, a good group by which to compare centers,
varied greatly from 17% to 47% (P< .001) (40). However,
the referring fertility center was not identiﬁed as a variable
that affects pregnancy outcome. The differences that were
observed between centers were due to other variables, such
as the type of mosaicism and the percentage of abnormal cells
(in the case of implantation).Study Limitations
There are several limitations to this study. First, it was not
sufﬁciently powered to detect differences between someVOL. 108 NO. 1 / JULY 2017subgroups of mosaic embryos. We are in the process of col-
lecting more data, which will enable us to provide a more
nuanced analysis of the potential pregnancy outcome of
different mosaic embryo types.
Approximately 20% of blastocysts are characterized as
mosaic after NGS (26). Moreover, in their investigation,
Maxwell et al. (24) observed that 9% of all transferred blasto-
cysts leading to ongoing pregnancies were mosaic. These obser-
vations are similar to our data (20%  41% OIR ¼ 8% of
ongoing pregnancies originating from a mosaic embryo). The
proportion of mosaic blastocyst stage embryos is ﬁve times
higher than that observed in chronic villus sampling (CVS;
1.84%) (41). However, CVS analysis does not routinely take
place with methodology as sensitive as NGS (42). Moreover,
wewere not able to determine if and how, similarly to themouse
data (35), the aneuploid cell line resolves itself in a mosaic blas-
tocyst, which leads to a normal ongoing pregnancy.
Mosaicism in fetuses and babies can result in congenital
abnormalities, autism, and mental retardation. Every chro-
mosome in a mosaic form has been described to be associated
with an abnormal phenotype. The spectrum of these pheno-
types ranges from normal development to severely affected,
and genotype-phenotype correlations are difﬁcult to be
established. This is further complicated by different rates of
abnormal cells between mosaic individuals as well as tissues
affected (36).
A critical, yet unresolved, question is whether preimplan-
tation mosaicism results in a higher chance of congenital ab-
normalities and affected children. To determine if replacing
mosaic blastocysts would result in a higher frequency than
the <2% of mosaic fetuses observed by means of CVS,
>700 pregnancies should be karyotyped. So far, data from
<200 ongoing pregnancies after replacement of mosaic em-
bryos has been collected (18, 27). Unfortunately, this
information could not be collected for the present study,
either because some of the centers did not report mosaicism
(center 3), the data was based on reanalysis with the use of
NGS of biopsied embryos after previous analysis by means
of aCGH and the embryos were deidentiﬁed (series 1), or the
majority of patients had not yet delivered, did not undergo
amniocentesis, or were lost to follow-up.
Ideally, all ongoing pregnancies and babies resulting af-
ter the transfer of mosaic embryos should be karyotyped and
followed for years through the child's development. For this
reason, we recommend, as well as the guidelines of PGDIS
(34) and Controversies in Preconception, Preimplantation,
and Prenatal Genetic Diagnosis (CoGen) (43), that prenatal
diagnosis with the use of amniocentesis is performed in preg-
nancies resulting from the transfer of mosaic embryos.
Noninvasive prenatal testing and CVS are inadequate because
they test the TE (the placenta) and not the ICM (the fetus).
Nevertheless, even a normal amniocentesis does not rule
out mosaicism in untested tissue types.Recommendations for Replacement of Mosaic
Embryos
Some laboratories are using an artiﬁcial cutoff to classify all
mosaicism events as normal or abnormal (usually 40% or 50%69
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONabnormal cells). In our opinion, this is likely to cause false
positives (discarding potentially viable embryos) and false
negatives (resulting in misdiagnoses and potential associated
complications). Instead, our opinion, ﬁrst expressed earlier
(25) and then incorporated in the PGDIS (34) and CoGen
(43) guidelines and supported by others (44), is that mosaics
need to be classiﬁed as a third category and deprioritized
for transfer after euploid embryos. Depending on the needs
of the patient, they could be considered for transfer if there
are no euploid embryos available and the patient is counseled
about the risks. This decision is patient dependent, because it
may be less appropriate, for example, for recurrent pregnancy
loss patients (higher risk of miscarriage) and patients not
wishing to do another PGS cycle.
The present study corrects some of the recommendations
recently published (34, 43, 44) in that there is no difference in
implantation rates after transferring trisomic, monosomi,c or
segmental mosaics. A notably poorer clinical outcome was
observed only with the transfer of complex mosaic
embryos, which have very little potential to implant. The
rest of the recommendations stand, such as deprioritizing
their transfer after euploid embryos, classifying them as
mosaic and not as euploid or aneuploid, and prioritizing
embryos with 20%–40% mosaicism over those with >40%
abnormal cells. Complex mosaic embryos could potentially
be considered for transfer in cases of women of advanced
age (>40 years) with a very poor reproductive history.
Transfer of complex mosaic embryos may give such
patients a small (10% in our data set) chance of achieving
an ongoing pregnancy. As already mentioned, a transfer of
a mosaic embryo (simple or complex mosaic) should always
take place after detailed counseling to ensure that the
patient is aware of and understands all associated risks.
The rest of the guidelines focus on which chromosomes
affected by mosaicism should be avoided for transfer, coin-
ciding with those at risk of being incompatible with life in
pure aneuploid form (chromosomes X, Y, 13, 18, 21), UPD
(chromosomes 7, 14, 15), or intrauterine growth restriction
(chromosome 16). Currently, however, there is no clear link
established between mosaicism at the blastocyst stage and
mosaicism seen during prenatal diagnosis, with some evi-
dence showing that the two are the result of independent
mechanisms (35, 45). Therefore, these recommendations
might be shown in the future to be too conservative. The
ever increasing use of NGS for the purposes of PGS along
with appropriate data collection and pregnancy follow-up
will hopefully provide a more detailed insight in the develop-
mental ability of mosaic blastocysts.
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SUPPLEMENTAL TABLE 1
Dilution experiments to validate detection of mosaicism by hr-NGS.
Average chromosome copy number
Ratio aneuploid:
euploid cells
(% abnormal)
Trisomy
13D euploid
cells (N[3)/SD
Trisomy
18D euploid
cells (N[3)/SD
45XOD euploid
cells (N[3)/SD
Trisomy
21D euploid
cells (N[3)/SD
Trisomy XXYD euploid
cells (N[3)/SD
-10p14-10p21 euploid
cells (N[3)/SD
5:0 (100%) 3.05/0.03 3.02/0.05 0.99/0.01 2.94/0.05 1.96/0.04 1.12/0.03
4:1 (80%) 2.93/0.06 2.78/0.05 1.11/0.02 2.71/0.07 1.84/0.05 1.21/0.02
3:2 (60%) 2.78/0.07 2.65/0.09 1.32/0.1 2.66/0.07 1.66/0.12 1.39/0.05
2:3 (40%) 2.45/0.05 2.41/0.05 1.6/0.02 2.43/0.04 1.52/0.1 1.57
1:4 (20%) 2.3/0.02 2.2/0.01 1.76/0.03 2.16/0.3 1.22/0.01 1.89/0.18
Note: N ¼ number of experiments.
Munne. Pregnancy outcome of mosaic blastocysts. Fertil Steril 2017.
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SUPPLEMENTAL TABLE 2
Dilution experiments to validate detection of mosaicism by hr-NGS.
Euploid Translocation %
Fragment size (MB) % Mosaicism
del(6)(q25.3-qter) dup(21)(q21.2-qter) del(6)(q25.3-qter) dup(21)(q21.2-qter)
46,XY 46,XX; del(6)(q25.3-qter),
dup(21)(q21.2-qter)
0 0 0 0 0
20 11 21 35 25
40 11 22 50 35
60 12 19 85 65
80 12 23 95 75
100 12 21 100 100
Euploid Translocation % dup(14)(q31.3-qter) del(18)(q22.1-qter) dup(14)(q31.3-qter) del(18)(q22.1-qter)
46,XY 46,XX; dup(14)(q31.3-qter),
del(18)(q22.1-qter)
0 0 0 0 0
20 0 12 0 8
40 20 12 35 40
60 19 12 50 70
80 19 13 65 80
100 19 12 70 100
Euploid Translocation % del(14)(q31.3-qter) dup(18)(q22.1-qter) del(14)(q31.3-qter) dup(18)(q22.1-qter)
46,XX 46,XY; del(14)(q31.3-qter),
dup(18)(q22.1-qter)
0 0 0 0 0
20 17 12 20 20
40 18 13 40 25
60 20 12 65 30
80 19 12 80 65
100 19 12 100 80
Euploid Translocation % dup(13)(pter-q22.3) del(18)(pter-q12.2) dup(13)(pter-q22.3) del(18)(pter-q12.2)
46,XX 46,XY; dup(13)(pter-q22.3),
del(18)(pter-q12.2)
0 0 0 0 0
20 51 30 25 25
40 53 29 50 35
60 53 28 60 50
80 53 28 90 80
100 54 28 100 100
Total % Average Standard Dev
0 0.0 0.0
20 19.0 11.6
40 37.1 7.6
60 59.3 17.7
80 77.1 10.4
100 92.9 12.5
Munne. Pregnancy outcome of mosaic blastocysts. Fertil Steril 2017.
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SUPPLEMENTAL TABLE 3
List of each embryo characteristics.
Embryo # Center Maternal age, y Mosaicism description % Mosaic Mosaic type Pregnancy outcome
1 3 35 Mos. Mono. 2 (20%), Mos.
Tris. 5 (40%), Mos. Tris
20 (45%)
45 Complex No pregnancy
2 4 34 Mos. partial Tris. 5q (20%) /
Mos. Tris. 14 (50%) /
Mos. partial Mono. 10q
(20%)
50 Complex No pregnancy
3 3 29 Mos. Tris. 4 (50%), Mos.Tris.
6 (40%), Mos. Mono 11
(35%), Mos Tris. 20
(35%)
50 Complex No pregnancy
4 4 40 Mos partial Tris. 10q (50%) /
Mos. partial Mono. 1p
(20%)/ Mos. partial
Mono. 4p (20%)
50 Complex No pregnancy
5 4 33 Mos. Trisomies 7/ Mos. Tris
15 /Mos. Mono.18
20 Complex No pregnancy
6 4 40 Mos. partial mono 20p /
Mos. Mono. 14 / Mos.
Mono. 21
20 Complex No pregnancy
7 4 36 Mos. monosomy 5 / Mos.
partial monoso 17q /
Mos. Partial mono. 19q
20 Complex No pregnancy
8 4 40 Mos. partial trisomy 17q /
Mos. Mono. 15 / Mos.
Mono. 21
20 Complex No pregnancy
9 4 36 Mos. Mono 2 (20%) / Mos.
partial Mono. 8p(20%) /
Mos. Partial Mono. 9p
(30%)
30 Complex No pregnancy
10 4 36 Mos. Tris. 5 (20%) /Mos. Tris
22 (20%) / Mos Tris 17
(20%) / mos Tris 21
(30%)
30 Complex No pregnancy
11 4 38 Mos. partial tris. 12p /
Mos.Tris 18/ Mos.Tris.19
/Mos.Tris.20/Mos.Tris.21
30 Complex No pregnancy
12 4 40 Mos. Tris 5 (20%)/ Mos.
Mono 4(30%)/ Mos.
Mon.6 (10%)/ Mos
Mono. 14(20%)/ Mos
Mono.19 (20%)
30 Complex No pregnancy
13 4 42 Mos. Tris 8 (30%)/ Mos. Tris
9 (20%)/ Mos Tris.12
(40%)/ Mos Tris. 16
(40%)/ Mos tris. 20
(20%)/ mos tris. 21
(30%) / Mos tris 22
(30%)/ Mos. mono 1
(20%) / Mos. Mono 17
(20%)
30 Complex No pregnancy
14 3 41 Mos. Tris 11 (35%), Mos Tris
14 (35%),Mos. Mono 15
(25%)
35 Complex No pregnancy
15 3 35 Mos Tris 5 (30%), Mos.
partial mono. 8pter-
q23.1 (35%), Mos Tris 13
(30%)
35 Complex No pregnancy
16 4 39 Mos. trisomy 2 (20%) / Mos.
partial mono. 10q (20%)
/Mos.mono 13q (40%)
40 Complex No pregnancy
17 4 39 Mos. Mono 4 (20%) / Mos.
Tris 8 (40%) / Mos. Tris
21 (40%)
40 Complex No pregnancy
18 4 38 Mos.Tris 7 /Mos.Tris. 17/
Mos.Mono 11
40 Complex No pregnancy
Munne. Pregnancy outcome of mosaic blastocysts. Fertil Steril 2017.
71.e3 VOL. 108 NO. 1 / JULY 2017
ORIGINAL ARTICLE: ASSISTED REPRODUCTION
SUPPLEMENTAL TABLE 3
Continued.
Embryo # Center Maternal age, y Mosaicism description % Mosaic Mosaic type Pregnancy outcome
19 4 32 Mos.Tris. 5 / Mos.Tris. 9 /
Mos.Tris. 15
20 Complex No pregnancy
20 3 30 Mos. Tris 13 (25%),Mos. Tris
14 (25%), Mos. Tris 21
(25%)
25 Complex No pregnancy
21 4 40 Mos.Mono 4 (20%) / Mos.
Mono 16 (20%) / Mos.
Mono 21 (30%) / Mos.
partial Tris. 3q / Mos
partial tris 16p (20%) /
Mos. Tris. 18 (20%)
30 Complex No pregnancy
22 1 33 Mos. Partial Mono. 18pter-
p11.21 / Mos. Trisomy 19
80 Double No pregnancy
23 4 42 Mos. partial Tris. 11q (50%) /
Mos. partial Tris. 16q
(20%)
50 Double No pregnancy
24 3 27 Mos. Partial mono 2q33.1-
qter (50%) / Mos. Mono
14 (30%)
50 Double Ongoing
25 1 39 Mos. Partial Mono. 7q11.22-
qter/Mos. Partial Mono.
9q21.11-qter
50 Double Ongoing
26 4 35 Mos. partial Tris 9q (50%) /
Mos. Partial Tris. Xq
(40%)
50 Double Ongoing
27 3 35 Mos. Trisomy 7 (25%), Mos.
Trisomy 8 (45%)
45 Double Ongoing
28 4 35 Mos partial Mono. 7p (50%)
/ Mos Mono 11 (40%)
50 Double Miscarried
29 3 33 Mos. Trisomy 14 (30%) /
Mos. partial mono
21q22.21-qter (40%)
40 Double No pregnancy
30 4 43 Mos. monosomy 5 / Mos.
trisomy 19
20 Double No pregnancy
31 4 36 Mos. trisomy 5 /Mos.
monosomy 21
20 Double No pregnancy
32 4 36 Mos. monosomy 21/Mos.
trisomy 22
20 Double No pregnancy
33 4 Mos. monosomy 3 (20%)
/Mos. trisomy 11 (30%)
30 Double No pregnancy
34 4 35 Mos. partial mono. 5q (40%)
/Mos. mono. 9 (20%)
40 Double No pregnancy
35 3 34 Mos. Monosomy 15 (40%),
Mos. Monosomy 18
(30%)
40 Double No pregnancy
36 3 37 Mos. Partial mono. 8pter-
q24.12 (35%) / Mos.
partial mono. 17pter-
q21.33 (35%)
35 Double No pregnancy
37 3 27 Mos. Trisomy 6 / Mos.
Trisomy 16
30 Double No pregnancy
38 4 33 Mos. Tris. 9 / Mos. Tris. 20 20 Double No pregnancy
39 4 42 Mos. Tris. 5/ Mos. Tris. 9 20 Double No pregnancy
40 3 43 Mos. Mono 6 (35%) / Mos.
Partial Mono 13q32.2-
qter (25%)
35 Double Ongoing
41 3 41 Mos. Mono 7 (30%) / Mos
Tris. 20 (35%)
35 Double Ongoing
42 4 36 Mos.partial tris. 5q /
Mos.partial tris.9q
30 Double Ongoing
43 3 35 Mos. Monosomy 14 (35%),
Mos. Monosomy 16
(30%)
35 Double Ongoing
44 4 30 Mos.Tris. partial Mono. 10q /
Mos. partial Tris. 14q
20 Double Ongoing
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45 4 43 Mos.partial tris. 3p (20%) /
Mos.partial tris. 5q
(30%)
30 Double Ongoing
46 4 42 Mos.partial tris. 4p (40%) /
Mos.partial Mono. 5p
(20%)
40 Double Ongoing
47 4 35 Mos. partial Mono. 2q /Mos.
partial Mono. 10q
40 Double Ongoing
48 3 35 Mos. Trisomy 5 (40%) / Mos.
Trisomy 19 (30%)
40 Double Ongoing
49 3 32 Mos. Monosomy 8 (40%) /
Mos. Monosomy
11(40%)
40 Double Miscarried
50 4 37 Mos. trisomies 20 / Mos. Tris.
21
40 Double Miscarried
51 1 32 Mos. Monosomy 22 50 Mono No pregnancy
52 1 43 Mos. Monosomy 16 80 Mono No pregnancy
53 2 41 Mos. Monosomy 16 80 Mono No pregnancy
54 2 42 Mos. Monosomy 19 80 Mono No pregnancy
55 2 42 Mos. Monosomy 6 80 Mono Ongoing
56 3 41 Mos. Monosomy 17 40 Mono No pregnancy
57 4 38 Mos. monosomy 21 20 Mono No pregnancy
58 3 25 Mos. Monosomy 18 25 Mono No pregnancy
59 3 36 Mos. Monosomy 3 30 Mono No pregnancy
60 3 32 Mos. Monosomy 13 30 Mono No pregnancy
61 3 33 Mos. Monosomy 22 35 Mono No pregnancy
62 3 37 Mos. Monosomy 18 20 Mono Ongoing
63 3 26 Mos. Monosomy 1 25 Mono Ongoing
64 3 35 Mos. Monosomy 6 25 Mono Ongoing
65 3 36 Mos. Monosomy 11 25 Mono Ongoing
66 3 34 Mos. Monosomy 13 25 Mono Ongoing
67 3 36 Mos. Monosomy 18 25 Mono Ongoing
68 3 37 Mos. Monosomy X 25 Mono Ongoing
69 3 40 Mos. Monosomy 5 30 Mono Ongoing
70 3 25 Mos. Monosomy 6 30 Mono Ongoing
71 3 32 Mos. Monosomy 15 30 Mono Ongoing
72 3 33 Mos. Monosomy 19 35 Mono Ongoing
73 4 43 Mos. Monosomy 7 20 Mono Ongoing
74 2 40 Mos. Monosomy 18 40 Mono Ongoing
75 3 37 Mos. Monosomy 13 25 Mono Miscarried
76 3 20 Mos. Monosomy X 25 Mono Miscarried
77 3 36 Mos. Monosomy X 30 Mono Miscarried
78 3 42 Mos. Monosomy 20 35 Mono Miscarried
79 3 37 Mos. Monosomy 21 35 Mono Miscarried
80 4 37 Mos. monosomy 17 20 Mono Miscarried
81 4 37 Mos. Monosomy 19 20 Mono No pregnancy
82 3 34 Mos. Monosomy 4 30 Mono No pregnancy
83 3 38 Mos. Partial monosomy
3pter-p22.3
45 Partial No pregnancy
84 3 28 Mos. partial monosomy
13q21.33-qter
45 Partial No pregnancy
85 1 40 Mos. Partial Trisomy 2q24.1-
qter
50 Partial No pregnancy
86 1 41 Mos. Partial Monosomy
3pter-p12.2
50 Partial No pregnancy
87 1 38 Mos. Partial Monosomy
7q11.21-qter
50 Partial No pregnancy
88 4 41 Mos. partial monosomy 6q 80 Partial No pregnancy
89 1 38 Mos. Partial Trisomy 6q22.2-
qter
60 Partial Miscarried
90 3 31 Mos. Partial monosomy 2q 45 Partial Ongoing
91 3 29 Mos. Partial monosomy
14q24.3-qter
45 Partial Ongoing
92 3 31 Mos. Partial monosomy
5q35.1-qter
50 Partial Ongoing
93 2 34 Mos. Partial Trisomy 20 50 Partial Ongoing
94 2 42 Mos. Partial monosomy 9 80 Partial Ongoing
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95 3 34 Mos. partial monosomy 1q 45 Partial No pregnancy
96 3 35 Mos. Partial monosomy
3pter-p22.2
25 Partial No pregnancy
97 3 33 Mos. Partial monosomy 2q 30 Partial No pregnancy
98 3 34 Mos. Partial Monosomy
12pter-p11.2
30 Partial No pregnancy
99 3 36 Mos. Partial monosomy
9q21.33-qter
40 Partial No pregnancy
100 4 38 Mos. partial monosomy 8p 20 Partial No pregnancy
101 1 30 Mos. Partial Monosomy
4pter-p11
30 Partial No pregnancy
102 4 37 Mos. partial monosomy 6p 30 Partial No pregnancy
103 3 35 Mos. Partial Trisomy
Xp11.22-qter
25 Partial Ongoing
104 3 37 Mos. Partial monosomy
5q14.1-qter
30 Partial Ongoing
105 3 40 Mos. Partial monosomy
14q32.12-qter
35 Partial Ongoing
106 3 43 Mos. Partial Monosomy
2pter-p23.3
40 Partial Ongoing
107 3 25 Mos. Partial monosomy
7q21.12-qter
40 Partial Ongoing
108 3 46 Mos. Partial Monosomy
11pter-p11.2
40 Partial Ongoing
109 3 38 Mos. Partial Trisomy Xpter-
p22.1
40 Partial Ongoing
110 2 42 Mos. Partial monosomy 12 30 Partial Ongoing
111 4 35 Mos. partial trisomy 14q 30 Partial Ongoing
112 4 33 Mos. partial monosomy 2p 40 Partial Ongoing
113 3 28 Mos. Partial Trisomy 8q23.3-
qter
25 Partial Miscarried
114 3 34 Mos. Partial Trisomy 9q 25 Partial Miscarried
115 3 25 Mos. Partial Monosomy
1p34.2-pter
30 Partial Miscarried
116 3 29 Mos. Partial monosomy
15q14.1-q15.1
35 Partial Miscarried
117 3 25 Mos. partial monosomy
4q21.21-qter
35 Partial No pregnancy
118 3 38 Mos. Trisomy 10 45 Tris No pregnancy
119 1 41 Mos. Trisomy 22 80 Tris Ongoing
120 1 41 Mos. Monosomy 19 80 Tris Miscarried
121 3 38 Mos. Trisomy 3 30 Tris No pregnancy
122 3 33 Mos. Trisomy 6 30 Tris No pregnancy
123 3 37 Mos. Trisomy 6 30 Tris No pregnancy
124 3 32 Mos. Trisomy 16 30 Tris No pregnancy
125 3 30 Mos. Trisomy 19 35 Tris No pregnancy
126 4 40 Mos. trisomy 10 20 Tris No pregnancy
127 4 26 Mos.Trisomy 14 20 Tris Ongoing
128 3 33 Mos. Trisomy 3 25 Tris Ongoing
129 3 37 Mos. Trisomy 5 25 Tris Ongoing
130 3 38 Mos. Trisomy 6 30 Tris Ongoing
131 3 31 Mos. Trisomy 8 30 Tris Ongoing
132 3 32 Mos. Trisomy 16 30 Tris Ongoing
133 3 38 Mos. Trisomy 16 35 Tris Ongoing
134 3 40 Mos. Trisomy 7 40 Tris Ongoing
135 3 38 Mos. Trisomy 19 40 Tris Ongoing
136 3 36 Mos. Trisomy 22 40 Tris Ongoing
137 4 35 Mos. trisomy 20 30 Tris Ongoing
138 1 30 Mosaic Partial Trisomy 4pter-
p15.2
60 Partial No pregnancy
139 1 44 Mosaic Partial Trisomy
10pter-p11.21
30 Partial Miscarried
140 2 40 Mos.Monosomy 18 30 Mono Ongoing
141 2 32 Mos.Partial mono 12 30 Partial Miscarried
142 2 32 Mosaic partil tri 14 30 Partial Miscarried
143 2 42 MOS. MONOSOMY 20 60 Mono Delivered
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Pregnancy outcome of embryos with one or two mosaic chromosomes. Per chromosome including only embryos with 1 or 2 abnormalities.
Per chromosome Monosomic events Trisomic events Segmental events Total Preg Lost Ong preg % ong preg
1 1 0 2 3 2 1 1 33
2 0 0 7 7 5 0 5 71
3 2 3 4 9 2 0 2 22
4 1 0 4 5 1 0 1 20
5 2 4 6 12 8 0 8 67
6 4 3 4 11 5 0 5 45
7 3 2 3 8 7 1 6 75
8 1 2 3 6 4 2 2 33
9 1 2 6 9 5 1 4 44
10 0 2 3 5 2 1 1 20
11 4 0 2 6 4 2 2 33
12 0 0 3 3 2 1 1 33
13 3 0 2 5 3 1 2 40
14 2 2 5 9 8 1 7 78
15 2 0 1 3 2 1 1 33
16 3 4 1 8 3 0 3 38
17 2 0 1 3 1 1 0 0
18 6 0 1 7 4 0 4 57
19 3 6 0 9 4 1 3 33
20 2 4 1 7 6 2 4 57
21 2 2 1 5 2 1 1 20
22 2 3 0 5 2 0 2 40
X 3 0 3 6 6 2 4 67
Total 49 39 63 151 88 19 69 46
1–12 19 18 47 84 47 9 38 45
13–22 27 21 13 61 35 8 26 43
P< .0001 NS
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Coefﬁcients, signiﬁcance and OR for the variables of the logistic
model for the dependent variables implantation rate (IR) and
ongoing implantation state (OIR). For each variable, the complex
mosaic type is the reference category.
Dependent variable Independent variable
Coefﬁcient
bi P value OR
IR x4 .013
Mono 2.857 .001 17.4
Double 2.459 .003 11.7
Tris 2.657 .002 14.3
Partial 2.200 .007 9.0
OIR x5
Non-complex 1.987 .009 7.3
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